NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Price, News & Analysis $0.30 +0.08 (+36.36%) Closing price 04:00 PM EasternExtended Trading$0.30 +0.00 (+1.33%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About PDS Biotechnology Stock (NASDAQ:PDSB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PDS Biotechnology alerts:Sign Up Key Stats Today's Range$0.26▼$0.6550-Day Range$0.20▼$0.8852-Week Range$0.20▼$1.55Volume485.83 million shsAverage Volume3.84 million shsMarket Capitalization$16.79 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview PDS Biotechnology Group, Inc. is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials. Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform. The company’s research initiatives include both off‐the‐shelf vaccines targeting shared tumor antigens and personalized approaches that present patient‐specific neoantigens. By integrating novel adjuvant technology with established cancer targets, PDS Biotechnology aims to generate durable T-cell responses and improve clinical outcomes in multiple solid tumor indications. Founded in 2007 and headquartered in San Diego, California, PDS Biotechnology conducts its research, translational studies, and early clinical development across facilities in the United States. The company partners with academic centers and biopharmaceutical organizations to advance its product candidates through global clinical trials. Under the leadership of CEO Bruce D. Montgomery and an experienced management team, PDS Biotechnology is dedicated to translating its platform innovations into next-generation immunotherapies for patients with cancer and chronic viral infections.AI Generated. May Contain Errors. Read More PDS Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScorePDSB MarketRank™: PDS Biotechnology scored higher than 43% of companies evaluated by MarketBeat, and ranked 601st out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPDS Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPDS Biotechnology has a consensus price target of $9.00, representing about 2,803.2% upside from its current price of $0.31.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about PDS Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PDS Biotechnology are expected to grow in the coming year, from ($0.45) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PDS Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.69% of the float of PDS Biotechnology has been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PDS Biotechnology has recently increased by 3.32%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.Search Interest6 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows12 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders8.40% of the stock of PDS Biotechnology is held by insiders.Percentage Held by Institutions26.84% of the stock of PDS Biotechnology is held by institutions.Read more about PDS Biotechnology's insider trading history. Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PDSB Stock News HeadlinesPDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding PressureSeptember 8 at 12:31 PM | quiverquant.comQPDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorksSeptember 8 at 8:30 AM | globenewswire.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 8 at 1:00 AM | Paradigm Press (Ad)HC Wainwright Predicts Higher Earnings for PDS BiotechnologyAugust 30, 2026 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for PDS Biotechnology (NASDAQ:PDSB)August 28, 2026 | americanbankingnews.comPDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2026 Financial ResultsAugust 13, 2026 | finanznachrichten.dePDS Biotech Reports $9.8 Million Second-Quarter 2026 Net LossAugust 13, 2026 | quiverquant.comQPDS Biotech Reports Second Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comSee More Headlines PDSB Stock Analysis - Frequently Asked Questions How have PDSB shares performed this year? PDS Biotechnology's stock was trading at $0.7698 at the start of the year. Since then, PDSB shares have decreased by 59.7% and is now trading at $0.31. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Corporation (NASDAQ:PDSB) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.05. When did PDS Biotechnology IPO? PDS Biotechnology (PDSB) raised $110 million in an initial public offering (IPO) on Thursday, October 1st 2015. The company issued 7,315,151 shares at $14.00-$16.00 per share. Who are PDS Biotechnology's major shareholders? PDS Biotechnology's top institutional shareholders include BlackRock Inc. (1.09%) and Bank of New York Mellon Corp (0.12%). View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2026Today9/08/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, PDSB's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PDSB CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees20Year Founded2005Price Target and Rating Average Price Target for PDS Biotechnology$9.00 High Price Target$15.00 Low Price Target$3.00 Potential Upside/Downside+2,900.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-708.18% Return on Assets-136.50% Debt Debt-to-Equity Ratio2.73 Current Ratio0.57 Quick Ratio0.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book1.67Miscellaneous Outstanding Shares55,970,000Free Float51,269,000Market Cap$16.79 million OptionableOptionable Beta1.46 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PDSB) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe Closest Thing to a Virtual AI Monopoly Wall Street Is IgnoringA little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PDSB Stock Alerts